Targeting mitochondrial dysfunction in amyotrophic lateral sclerosis: a systematic review and meta-analysis

Author:

Mehta Arpan R12345ORCID,Walters Rachel234,Waldron Fergal M6,Pal Suvankar234,Selvaraj Bhuvaneish T124,Macleod Malcolm R234,Hardingham Giles E147,Chandran Siddharthan12348,Gregory Jenna M12349ORCID

Affiliation:

1. UK Dementia Research Institute, University of Edinburgh, Edinburgh, UK

2. Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK

3. The Anne Rowling Regenerative Neurology Clinic, University of Edinburgh, Edinburgh, UK

4. The Euan MacDonald Centre, University of Edinburgh, Edinburgh, UK

5. Nuffield Department of Clinical Neurosciences, University of Oxford, Oxford, UK

6. Institute of Evolutionary Biology and Centre for Immunity Infection and Evolution, University of Edinburgh, Ashworth Laboratories, Edinburgh, UK

7. Centre for Discovery Brain Sciences, University of Edinburgh, Edinburgh, UK

8. Centre for Brain Development and Repair, inStem, Bangalore, India

9. MRC Edinburgh Brain Bank, Academic Department of Neuropathology, University of Edinburgh, Edinburgh, UK

Abstract

Abstract Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral sclerosis. The aim of this systematic review was to assess the efficacy of targeting mitochondria as a potential therapeutic target in amyotrophic lateral sclerosis. Preclinical studies written in the English language were identified with no restrictions on publication date from PubMed, Medline and EMBASE databases. All studies adopting interventions targeting mitochondria to treat amyotrophic lateral sclerosis in genetic or drug-induced organism models were considered for inclusion. A total of 76 studies were included in the analysis. Survival data were extracted, and the meta-analysis was completed in RevMan 5 software. We show that targeting mitochondrial dysfunction in amyotrophic lateral sclerosis results in a statistically significant improvement in survival (Z = 5.31; P < 0.00001). The timing of administration of the intervention appears to affect the improvement in survival, with the greatest benefit occurring for interventions given prior to disease onset. Interventions at other time points were not significant, although this is likely to be secondary to a lack of publications examining these timepoints. The quality score had no impact on efficacy, and publication bias revealed an overestimation of the effect size, owing to one outlier study; excluding this led to the recalculated effect size changing from 5.31 to 3.31 (P < 0.00001). The extant preclinical literature indicates that targeting mitochondrial dysfunction may prolong survival in amyotrophic lateral sclerosis, particularly if the intervention is administered early. A limitation of current research is a significant bias towards models based on superoxide dismutase 1, with uncertainty about generalisability to amyotrophic lateral sclerosis with an underlying TAR DNA binding protein 43 proteinopathy. However, further mechanistic research is clearly warranted in this field.

Funder

Medical Research Council

Motor Neurone Disease Association

Anne Rowling Regenerative Neurology Clinic

Dementia Research Institute

Medical Research Council, Alzheimer’s Research UK

Academy of Medical Sciences

Publisher

Oxford University Press (OUP)

Subject

General Earth and Planetary Sciences,General Environmental Science

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3